Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer.

Miyake H, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A.

Anticancer Res. 2019 Mar;39(3):1391-1396. doi: 10.21873/anticanres.13253.

PMID:
30842173
2.

Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.

Gravis G, Boher JM, Fizazi K, Joly F, Priou F, Marino P, Latorzeff I, Delva R, Krakowski I, Laguerre B, Walz J, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Oudard S.

Eur Urol. 2015 Aug;68(2):196-204. doi: 10.1016/j.eururo.2014.09.022. Epub 2014 Sep 30.

PMID:
25277272
3.

Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer.

Mikah P, Krabbe LM, Eminaga O, Herrmann E, Papavassilis P, Hinkelammert R, Semjonow A, Schrader AJ, Boegemann M.

BMC Cancer. 2016 Mar 14;16:214. doi: 10.1186/s12885-016-2260-y.

4.

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.

BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.

5.
6.

Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.

Miyoshi Y, Yoneyama S, Kawahara T, Hattori Y, Teranishi JI, Ohta JI, Takebayashi S, Yokomizo Y, Hayashi N, Uemura H.

Urol Int. 2017;99(4):400-405. doi: 10.1159/000477131. Epub 2017 Jun 14.

PMID:
28609769
7.

Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer.

Metwalli AR, Rosner IL, Cullen J, Chen Y, Brand T, Brassell SA, Lesperance J, Porter C, Sterbis J, McLeod DG.

Urol Oncol. 2014 Aug;32(6):761-8. doi: 10.1016/j.urolonc.2014.03.024. Epub 2014 Jun 11.

8.
9.
10.

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.

Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW.

Urology. 2013 Jun;81(6):1297-302. doi: 10.1016/j.urology.2013.01.061. Epub 2013 Apr 9.

PMID:
23582482
11.

Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.

Park YH, Hwang IS, Jeong CW, Kim HH, Lee SE, Kwak C.

J Urol. 2009 Jun;181(6):2520-4; discussion 2525. doi: 10.1016/j.juro.2009.01.104. Epub 2009 Apr 16.

PMID:
19371894
12.

The effect of time to castration resistance on overall survival and success of docetaxel treatment in castration resistant prostate cancer patients.

Suer E, Hamidi N, Akpinar C, Gokce MI, Gulpinar O, Turkolmez K, Beduk Y, Baltaci S.

Urol J. 2019 Jan 13. doi: 10.22037/uj.v0i0.4497. [Epub ahead of print]

13.

Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis.

Sasaki T, Onishi T, Hoshina A.

Prostate Cancer Prostatic Dis. 2011 Sep;14(3):248-52. doi: 10.1038/pcan.2011.14. Epub 2011 Apr 19.

PMID:
21502970
14.

Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.

Teoh JY, Tsu JH, Yuen SK, Chan SY, Chiu PK, Lee WM, Wong KW, Ho KL, Hou SS, Ng CF, Yiu MK.

Ann Surg Oncol. 2015 Apr;22(4):1385-91. doi: 10.1245/s10434-014-4105-8. Epub 2014 Sep 19.

PMID:
25234025
15.

The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.

Shiota M, Yokomizo A, Adachi T, Koga H, Yamaguchi A, Imada K, Takeuchi A, Kiyoshima K, Inokuchi J, Tatsugami K, Naito S.

Jpn J Clin Oncol. 2014 Sep;44(9):860-7. doi: 10.1093/jjco/hyu081. Epub 2014 Jun 20.

PMID:
24951829
16.

Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, Hetherington J, Hoskin PJ, Jones RJ, Laing R, Lester JF, McLaren D, Parker CC, Parmar MKB, Ritchie AWS, Russell JM, Strebel RT, Thalmann GN, Mason MD, Sydes MR.

Eur Urol. 2015 Jun;67(6):1028-1038. doi: 10.1016/j.eururo.2014.09.032. Epub 2014 Oct 6.

17.

Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.

Miyamoto S, Ito K, Miyakubo M, Suzuki R, Yamamoto T, Suzuki K, Suzuki K, Yamanaka H.

Prostate Cancer Prostatic Dis. 2012 Mar;15(1):75-86. doi: 10.1038/pcan.2011.47. Epub 2011 Oct 11.

PMID:
21986985
18.

Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy.

Wang Y, Xu F, Pan J, Zhu Y, Shao X, Sha J, Wang Z, Cai Y, Liu Q, Dong B, Xue W, Huang Y.

BMC Cancer. 2016 May 24;16:329. doi: 10.1186/s12885-016-2363-5.

19.

Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study.

Shimabukuro T, Sakano S, Matsuda K, Kamiryo Y, Yamamoto N, Kaneda Y, Nasu T, Baba Y, Suga A, Yamamoto M, Aoki A, Takai K, Yoshihiro S, Konishi M, Imoto K, Matsuyama H.

Int J Clin Oncol. 2013 Feb;18(1):62-7. doi: 10.1007/s10147-011-0344-x. Epub 2011 Nov 3.

PMID:
22068464
20.

Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.

Sonpavde G, Pond GR, Berry WR, de Wit R, Armstrong AJ, Eisenberger MA, Tannock IF.

Urol Oncol. 2012 Sep;30(5):607-13. doi: 10.1016/j.urolonc.2010.07.002. Epub 2010 Oct 2.

PMID:
20888271

Supplemental Content

Support Center